Ventral Posterior Nucleus Role in Neuropathic Pain, Neuromyelitis Optica Spectrum Disorders
Thalamic ventral posterior nucleus volume is associated with neuropathic pain intensity in patients with neuromyelitis optica spectrum disorders.
Thalamic ventral posterior nucleus volume is associated with neuropathic pain intensity in patients with neuromyelitis optica spectrum disorders.
The terminal complement inhibitor eculizumab reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).
Patients with neuromyelitis optica spectrum disorder who experience relapses use more pain medication than non-relapsing patients.
The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Satralizumab monotherapy may reduce the risk for neuromyelitis optics spectrum disorder relapse, and has a favorable safety profile.
Little guidance has been issued on how to manage patients with COVID-19 and coexisting neurological disorders.
Inebilizumab is superior to placebo in reducing the risk for a neuromyelitis optica spectrum disorder attack.
The FDA has accepted the Biologics License Application (BLA) for satralizumab (Genentech) for the treatment of neuromyelitis optica spectrum disorder.
The use of immunosuppressive therapy (IST) prior to pregnancy in women with neuromyelitis optica spectrum disorder (NMOSD) is not associated with negative long-term outcomes.